Mark Petronczki

Mark Petronczki

Auto-generated profile, based on publicly available information

Mark Petronczki

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Current Biology
Verified
Journal Article
Closed access
MSMartin Steegmaier
Martin Steegmaier
MHMatthias Hoffmann
Matthias Hoffmann
ABAnke Baum
Anke Baum
PLPéter Lénárt
Péter Lénárt
MPMark Petronczki
Mark Petronczki
WRWolfgang J. Rettig
Wolfgang J. Rettig

1 February 2007 in Current Biology
Verified
Journal Article
Closed access
PLPéter Lénárt
Péter Lénárt
MPMark Petronczki
Mark Petronczki
MSMartin Steegmaier
Martin Steegmaier
BFBarbara Di Fiore
Barbara Di Fiore
JLJesse J. Lipp
Jesse J. Lipp
JPJan-Michael Peters
Jan-Michael Peters

1 February 2003 in Cell
Verified
Journal Article
Closed access
MPMark Petronczki
Mark Petronczki
MSMaria F Siomos
Maria F Siomos
KNKim Nasmyth
Kim Nasmyth

15 March 2006 in Nature
Verified
Journal Article
Closed access
PDF file
CRChristian G. Riedel
Christian G. Riedel
VKVittorio L. Katis
Vittorio L. Katis
YKYuki Katou
Yuki Katou
SMSaori Mori
Saori Mori
TITakehiko Itoh
Takehiko Itoh
KNKim Nasmyth
Kim Nasmyth

1 May 2008 in Developmental Cell
Verified
Journal Article
Closed access
MPMark Petronczki
Mark Petronczki
PLPéter Lénárt
Péter Lénárt
JPJan-Michael Peters
Jan-Michael Peters

19 August 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MHMarco H. Hofmann
Marco H. Hofmann
MGMichael Gmachl
Michael Gmachl
JRJuergen Ramharter
Juergen Ramharter
FSFabio Savarese
Fabio Savarese
DGDaniel Gerlach
Daniel Gerlach
NKNorbert Kraut
Norbert Kraut
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited success because of activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback node, represents an effective approach to treat KRAS-driven cancers. We report the discovery of a highly potent, selective, and orally bioavailable small-molecule SOS1 inhibitor, BI-3406, that binds to the catalytic domain of SOS1, thereby preventing the interaction with KRAS. BI-3406 reduces formation of GTP-loaded RAS and limits cellular proliferation of a broad range of KRAS-driven cancers. Importantly, BI-3406 attenuates feedback reactivation induced by MEK inhibitors and thereby enhances sensitivity of KRAS-dependent cancers to MEK inhibition. Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors. Significance: To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406 activity and identification of MEK inhibitors as effective combination partners provide an attractive therapeutic concept for the majority of KRAS-mutant cancers, including those fueled by the most prevalent mutant KRAS oncoproteins, G12D, G12V, G12C, and G13D. See related commentary by Zhao et al., p. 17. This article is highlighted in the In This Issue feature, p. 1